Alatrofloxacin: Difference between revisions
Appearance
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: ''). |
Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or [[user talk:Che... |
||
Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
⚫ | |||
| Watchedfields = changed |
|||
⚫ | |||
| IUPAC_name = 7-[(1''R'',5''S'')-6-{[(2''S'')-1-{[(2''S'')-<br>2-aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-<br>3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-<br>6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid |
| IUPAC_name = 7-[(1''R'',5''S'')-6-{[(2''S'')-1-{[(2''S'')-<br>2-aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-<br>3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-<br>6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid |
||
| image = Alatrofloxacin.svg |
| image = Alatrofloxacin.svg |
||
Line 29: | Line 28: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|changed|??}} |
|||
| CAS_number = 157182-32-6 |
| CAS_number = 157182-32-6 |
||
| CAS_supplemental = {{CAS|157605-25-9}} |
| CAS_supplemental = {{CAS|157605-25-9}} |
||
Line 38: | Line 38: | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 21106252 |
| ChemSpiderID = 21106252 |
||
| UNII_Ref = {{fdacite| |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 7QVV6I50DT |
| UNII = 7QVV6I50DT |
||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
Revision as of 13:48, 21 October 2011
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Elimination half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H25F3N6O5 |
Molar mass | 558.509 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
|
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 that encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
See also
References
- ^ "PubChem CID 5489474".
- ^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980. PMID 16735322.